Introduction {#Sec1}
============

Breast cancer is one of the most common cancers in women worldwide \[[@CR1]\]. It is a heterogeneous disease with differential responses to therapy \[[@CR2]\]. Triple-negative breast cancers exhibit resistance to various chemotherapies and are the most aggressive tumors with a 5-year survival rate of \<30% \[[@CR3]\]. Relapse and patient mortality results in part from tumor spread and metastasis \[[@CR4]\].

Signals generated from transmembrane integrin receptors are one of the molecular drivers of tumor metastasis \[[@CR5]\]. Integrins sense changes in extracellular matrix composition and tension and in turn activate focal adhesion kinase (FAK), a 115 kDa cytoplasmic tyrosine kinase \[[@CR6]\]. FAK mRNA levels are elevated in approximately 26% of breast tumors, and high FAK protein levels are common in human epidermal growth factor 2 (HER2)-positive \[[@CR7]\] and triple-negative tumors \[[@CR8]\]. FAK overexpression is associated with increased tumor growth, an invasive phenotype, higher histological grade, and poor patient prognosis \[[@CR8]-[@CR10]\]. Mouse tumor models reveal that FAK knockout prevents multiple aspects of breast carcinoma tumor initiation and progression \[[@CR11]-[@CR14]\].

Studies evaluating genetic or pharmacological inactivation of FAK activity within tumor cells have linked FAK signaling to the promotion of tumor growth, angiogenesis, and tumor metastasis \[[@CR6],[@CR15]\]. *In vitro*, sub-micromolar concentrations of pharmacological FAK inhibitors can prevent tumor cell growth under three-dimensional but not necessarily two-dimensional conditions \[[@CR16]-[@CR19]\]. This is associated with tumor cells expressing low merlin tumor suppressor expression and β1 and β5 integrin signaling linkages \[[@CR19]-[@CR21]\]. Tumor spheroid survival is highly dependent on FAK activity \[[@CR16],[@CR21]\]. These FAK-associated signals can be generated at the cell surface in association with integrins. However, because FAK also translocates to the nucleus when cells are grown in suspension \[[@CR22]\], and nuclear FAK can alter gene expression \[[@CR23],[@CR24]\], the location for FAK-mediated survival signal generation within tumor spheroids remains undefined.

It also remains unclear whether FAK activity within a tumor spheroid impacts the expression of target proteins selectively required for three-dimensional or anchorage-independent cell survival. To this end, tumor spheroids share many characteristics of cancer stem cells \[[@CR25]\]. Several proteins associated with the nucleolus play important roles in genome protection, ribosome synthesis, and stem cell proliferation \[[@CR26],[@CR27]\]. Nucleostemin (NS), a 62-kDa nucleolar protein, regulates proliferation in stem and cancer cells \[[@CR28],[@CR29]\]. Interestingly, NS promotes anchorage-independent mammary tumor spheroid growth \[[@CR30]\] and is increased during mouse mammary tumor progression \[[@CR31]\], and breast cancer patients with NS-positive tumors exhibit significantly shorter disease-free survival \[[@CR32]\]. NS is a guanine triphosphate (GTP)-binding protein that shuttles between the nucleolus and nucleoplasm \[[@CR33]\]. Inhibition of guanine nucleotide synthesis triggers nucleolar stress, NS movement to the nucleoplasm, and NS proteasomal degradation \[[@CR34],[@CR35]\]. Although increased levels of reactive oxygen species can enhance NS protein stability \[[@CR36]\], the signaling pathways controlling NS levels in tumor cells remain undefined.

Here, we show that FAK and NS are part of a signaling axis promoting breast carcinoma tumor progression. Pharmacological or genetic FAK inhibition reduces NS levels in cells grown as tumors by regulating its stability. FAK activity and NS are required for anchorage-independent spheroid growth. Cell fractionation analyses revealed active FAK association with nucleoli and a complex between FAK, NS, Akt, and mammalian target of rapamycin (mTOR) was detected by co-immunoprecipitation with green fluorescent tagged NS. Mechanistically, activated Akt kinase expression was sufficient to rescue effects of FAK inhibition and rapamycin treatment triggered loss of NS protein in cells with activated Akt-mTOR signaling. Our studies support a non-canonical role for nucleolar-associated FAK signaling and Akt-mTOR activation in the maintenance of NS protein expression.

Methods {#Sec2}
=======

Antibodies and reagents {#Sec3}
-----------------------

Antibodies to pY397 FAK (clone 141--9) were from Life Technologies (Carlsbad, CA, USA). Antibodies to Akt (clone C67E7), pS473 Akt (9271), mTOR (2983) and pS65 4E-BP1 (9451) were from Cell Signaling (Beverly, MA, USA). Antibodies to NS (70346), B23 (clone FC82291), and pY397 FAK (4803) were from Abcam (Cambridge, MA, USA). Anti-human nucleolin (clone D-6) and anti-Lamin B (sc-6216) were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Monoclonal (clone 4.47) and polyclonal antibodies to FAK (06--543) were from Millipore (Bedford, MA, USA). Antibodies to β-actin (clone AC-74, Sigma) and GAPDH (clone GT239) were Sigma (St. Louis, MO, USA) and GenTex (Irvine, CA, USA), respectively. Monoclonal antibody (clone B34) and polyclonal (A-6455) to GFP and were from Covance (Princeton, NJ, USA) and Life Technologies, respectively. Plasmid pLKO.1-puro non-target shRNA control (SHC016) was from Mission-Sigma (St. Louis, MO, USA). Human NS shRNA lentivirus plasmids (in pLKO.1-puro) were from Mission-Sigma (clone IDs 206826.1-683s21c1 and 206826.1-1310s21c). Plasmid pBabe-puro and pBabe-Puro-Myr-Flag-Akt1 (15294) were from Addgene (Cambridge, MA, USA). MG132 and rapamycin were from Calbiochem (San Diego, CA, USA) and LC Laboratories (Woburn, MA, USA), respectively. PF-562,271 (PF-271) was synthesized as described \[[@CR37]\] and PND-1186 (renamed VS-4718 by Verastem Inc.) was from Poniard (San Francisco, CA, USA). For *in vitro* studies, PF-271 and PND-1186 were dissolved in dimethyl sulfoxide (DMSO).

Cells {#Sec4}
-----

The 4T1 murine mammary carcinoma cells, BT474, MDA-MB-231 and MDA-MB-468 human breast carcinoma cells were from American Type Culture Collection. MCF-7 human breast carcinoma cells were obtained from David Cheresh (UCSD, University California San Diego, CA, USA). Selection of highly metastatic mCherry 4T1 cells named 4T1L was performed by isolation and expansion of cells from lung metastases \[[@CR15]\]. FAK shRNA-expressing HEY cells (ovarian cancer cells) were generated and cultivated as described \[[@CR19]\]. Table [1](#Tab1){ref-type="table"} lists source, culture conditions, and selective DNA sequencing information for the breast carcinoma cells used in this study.Table 1**Background information on the breast carcinoma cell lines used in this studyCellsSourceCulture mediaCancer typeSelected genetic events** \[[@CR51]\]**MCF7**D. Cheresh (UCSD)(1)Invasive ductal carcinoma \[[@CR52]\]PIK3CA (E545K)**BT474**ATCC(1)Invasive ductal carcinoma \[[@CR52]\]PIK3CA (K111N)TP53 (E285K)HER2 (amplification)**MDA-MB-231**ATCC(2)Adenocarcinoma \[[@CR52]\]BRAF (G464V)KRAS (G13D)TP53 (R280K)**MDA-MB-468**ATCC(2)Adenocarcinoma \[[@CR52]\]PTEN (V85_splice)**4T1L**D Schlaepfer (UCSD)(2)Selection of metastatic mCherry-labeled 4 T1 cells by isolation and culture of cells from 4 T1 lung metastases \[[@CR15]\](undetermined)(1) Roswell Park Memorial Institute medium supplemented with 10% FBS, 0.1 mM non-essential amino acids, 2 mM glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin. (2) DMEM supplemented with 10% FBS, 0.1 mM non-essential amino acids, 2 mM glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin.

DNA and retroviral constructs {#Sec5}
-----------------------------

Short-hairpin (shRNA) targeting human FAK and a scrambled (Scr) control in pLentiLox 3.7-puro were created as described \[[@CR22]\]. Lentiviral transduced cells were selected by growth in puromycin, clones were isolated by single cell sorting, and characterized by anti-FAK immunoblotting as described \[[@CR17]\]. Three cell clones were pooled, expanded, and stored frozen as Scr- or FAK shRNA-expressing MDA-MB-231 cells. Green fluorescent protein (GFP)-tagged murine FAK wildtype (WT) or murine FAK kinase-dead (KD, K454R) in pCDH1-MCS1-EF1-Puro (System Biosciences) were stably re-expressed by lentiviral transduction and puromycin selection. MDA-MB-231 FAK-WT and FAK-KD cells were stably transduced with a myristoylated and membrane-targeted form of Akt (Addgene) via retroviral transduction as described \[[@CR22]\]. Cells were transduced with fluorescent mCherry protein (pmCherry-C1, Clontech) using a lentivirus expression vector (pCDH-CMV-MSC1, System Biosciences) as described \[[@CR17]\] prior to initiation of mouse tumor studies. Human NS was amplified by PCR and subcloned into pEGFP-C1 (Clonetch) from pBabe-NS provided by Frederic Lessard and Gerardo Ferbeyre (Université de Montréal). MDA-MB-231 cells were transiently transfected using jetPRIME (PolyPlus Transfection) GFP or GFP-NS plasmid DNA (10 μg).

Cell growth {#Sec6}
-----------

For adherent growth, 1 × 10^4^ cells in 2 ml growth media were distributed in 6-well plates (Costar, tissue culture treated). Between 24 and 120 hours, all cells were collected by limited trypsin-EDTA treatment, a single cell suspension was prepared, and the viable total cell number determined by automated trypan blue staining and counting (ViCell XR, Beckman). For three-dimensional cultures, 10,000 cells were embedded in 1% methylcellulose diluted in growth media and plated onto 6-well poly-hyodroxyethyl methacrylic acid (poly-HEMA)-coated plates (Costar). At the indicated time, colonies were imaged in phase contrast, and enumerated by counting five different fields of each well. All experimental points were performed in triplicate and repeated at least two times.

Mice {#Sec7}
----

Female NOD/SCID (Harlan Laboratories, Indianapolis, IN, USA) mice were housed in pathogen-free conditions according to the Association for the Assessment and Accreditation for Laboratory Animal Care guidelines. Studies were performed with approval of the University of California, San Diego Institutional Animal Care and Use Committee protocols. No body weight loss or morbidity was associated with the study protocols.

Mouse tumor studies {#Sec8}
-------------------

MDA-MB-231 (0.5 × 10^6^) cells in 10 μl of growth factor-depleted Matrigel (BD Biosciences) were injected into the T4 mammary fat pad of 8- to 10-week-old mice using a Hamilton syringe and a 28-gauge needle. Tumors were measured every 3 to 4 days with digital vernier calipers and tumor volume (mm^3^) was calculated using the formula:$$\documentclass[12pt]{minimal}
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where V = volume, a = length, mm and b = width, mm.

Sites of spontaneous lung metastasis were imaged using the OV100 Small Animal Imaging System (Olympus) with a set exposure and quantified by combined dorsal and ventral fluorescent images using Image J (v1.46r) with a set threshold.

Immunoblotting {#Sec9}
--------------

Cell lysis buffer (1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 50 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) pH 7.4, 150 mM NaCl, 10% glycerol, 1.5 mM MgCl~2~, 1 mM EGTA, 10 mM sodium pyrophosphate, 100 mM NaF, 1 mM sodium orthovanadate, and 10 μg/mL leupeptin) was used to extract proteins from cultured cells and tumors were homogenized (Pro 200 tissue homogenizer, Pro Scientific) in lysis buffer without sodium deoxycholate and SDS. Total protein levels were determined by Bradford assay (Thermo Scientific), proteins were resolved by NuPAGE 4-12% Tris-Bis gels (Invitrogen), and transferred to polyvinylidene difluoride membranes (Immobilon, Millipore) for antibody immunoblotting. Relative expression levels and phosphospecific antibody reactivity were measured by densitometry analyses of blots using Image J. For immunoprecipitation, lysates were diluted threefold in cell lysis buffer and incubated with polyclonal anti-FAK antibody or anti-GFP at 4°C, overnight. After incubation with protein A Plus agarose beads (Millipore) for 1 hour at 4°C, antibodies were collected by centrifugation, washed twice with cell lysis buffer and resolved by PAGE.

Nucleolar isolation {#Sec10}
-------------------

Cell fractionation to isolate nucleoli was performed as described \[[@CR38]\] with some modifications. Briefly, 0.5 × 10^7^ cells were collected by trypsinization and processed, or plated onto poly-HEMA-coated plates for 4 hours prior to processing. Cells were lysed using a hypotonic solution (10 mM HEPES pH 7.9, 10 mM KCl, 1.2 mM MgCl~2~, 0.3% NP-40 and 0.5 mM dithiothreitol) and dounce homogenized with a tight pestle. Intact nuclei were pelleted by centrifugation (228 × g for 5 minutes) and the cytoplasmic supernatant saved and stored frozen at −20°C. Nuclei were resuspended in 0.25 M sucrose, 10 mM MgCl~2~ solution (S1 solution) and layered over 3 mL 0.35 M sucrose, 0.5 mM MgCl~2~ solution (S2 solution) and centrifuged at 1430 × g for 5 minutes at 4°C. The clean, pelleted nuclei were resuspended in S2 solution and sonicated eight times (10-s bursts at 1-minute intervals) using a 450 Branson Sonifier and microtip probe at power setting 4. The sonicate was assessed by light microscopy to certify the absence of intact nuclei and the presence of nucleoli as dense refractive bodies. The sonicated sample was layered over a 0.88 M sucrose, 0.5 mM MgCl~2~ solution (S3 solution) and centrifuged for 10 minutes at 2,800 g at 4°C. The pellet contained the nucleoli while the supernatant consisted of the nucleoplasmic fraction. The nucleolar pellet was washed twice with S2 solution (5 minutes at 2,000 g) and protein extracts obtained by cell lysis buffer addition.

Immunohistochemistry {#Sec11}
--------------------

Tumors were divided into half and either processed for protein lysates (as above) or fixed in formalin for staining using specific antibodies or H&E for histological evaluation. A paraffin-embedded tumor tissue array (BR8013, US Biomax) containing normal and tumor breast samples and MDA-MB-231 tumors were deparaffinized, rehydrated, processed for antigen retrieval, and peroxidase quenched as described \[[@CR17]\]. Tissues were blocked (PBS with 1% BSA, and 0.1% Triton X-100) for 45 minutes at room temperature (RT) and incubated with anti-pY397 FAK (1:100), or anti-NS (1:100) in blocking buffer overnight. Biotinylated goat-anti-rabbit IgG, Vectastain ABC Elite, and diaminobenzidine were used to visualize antibody binding. Slides were counterstained with hematoxylin or methyl green. Images were captured using an upright microscope (Olympus BX43) with a color camera (Olympus SC100). For GFP analyses, cells were plated in coverslips, fixed with paraformaldehyde (PFA) (4%) for 10 minutes and cell nuclei were visualized by incubation with 1:50,000 dilution of Hoechst 33342 (Invitrogen). Images were sequentially captured at 20× magnification (UPLFL objective, 1.3 NA; Olympus) using a monochrome charge-coupled camera (ORCA ER; Hamamatsu), an inverted microscope (IX81; Olympus), and Slidebook software (v5.0, Intelligent Imaging). Images were pseudo-colored, overlaid, merged using Photoshop (Adobe), and quantified using Image J.

Cell cycle analyses {#Sec12}
-------------------

Cells were collected as a single cell suspension by limited trypsin treatment and fixed in 70% ethanol and stored at −20°C overnight. Cells were incubated in 100 μl of PBS containing DNAse-free RNAse (100 μg/mL, Qiagen) and after 45 minutes, propidium iodide (PI, 10 μg/mL) was added prior to flow cytometry. Analyses were performed using FlowJo software (v9.5.1).

Real-time quantitative PCR analyses {#Sec13}
-----------------------------------

RNA was extracted from FAK-WT and FAK-KD MDA-MB-231 cells using the RNeasy Kit (Qiagen). NS and actin (used as normalization control) were amplified with specific primers (below). For PCR we used 480 SYBR green master mix (BioPioneer) with a LighterCycler 480 (Roche). Cycle conditions were 40 cycles of 94°C for 15 s, 56°C for 30 s, and 72°C for 30 s. The normalized mRNA level was defined as DCt = (target gene)-Ct (reference gene) and presented as fold difference between control and test samples (DCt control-DCt test). Actin forward 5′ GCGAGCACAGAGCCTCGCCTTTG 3′, actin reverse 5′ ACGACGAGCGCGGCGATATCAT 3′, NS forward 5′ TATCCATGGGGCTTACAAGG 3′ and NS reverse 5′ CTGGACTTCGCAGAGCAAG 3′.

Database analyses {#Sec14}
-----------------

Expression array data were evaluated using the online Kaplan-Meier plotter \[[@CR39]\]. The datasets (2014) were from Affymetrix HG-U133A, HG-U133 Plus 2.0, and HG-U133A 2.0 microarrays that share 22,277 probe sets in common. Overall survival (OS) information was from the Gene Expression Omnibus (GEO) (Affymetrix microarrays only), European Genome-Phenome Archive (EGA), and The Cancer Genome Atlas (TCGA) databases. The probe set used for PTK2 (FAK) analyses was 208820_at, NS was 217850_at, B23 was 221923_s\_at and NCL (nucleolin) was 200610_s\_at. Query parameters were: OS, split patients by median, auto-select best cutoff, and follow-up threshold of 10 years. For OS analyses, the signal range of the probes was as follows: PTK2 probe, 346--8042; NS probe, 1697--13661; B23 probe, 642--17106, and NCL probe, 1697--13661. The auto-cutoff value was 2515, 1802, 3772, and 6309 for PTK2, NS, B23, and NCL, respectively. Restriction analyses were estrogen receptor (ER) status (all), progesterone receptor (PR) status (all), lymph node status (all), grade (all), and intrinsic subtype (all). In total, 741 patient samples were analyzed.

Statistics {#Sec15}
----------

Significant difference between groups was determined using one-way analysis of variance (ANOVA) with Tukey post hoc analysis. Differences between paired data were determined using the unpaired two-tailed Student's *t*-test. All statistical analyses were performed using Prism (GraphPad Software, v5.0d). *P*-values \<0.05 were considered significant.

Results {#Sec16}
=======

FAK inhibitor reduction in breast carcinoma anchorage-independent growth is associated with decreased nucleostemin levels {#Sec17}
-------------------------------------------------------------------------------------------------------------------------

Nanomolar concentrations of pharmacological FAK inhibitors prevent 4T1 breast carcinoma growth under three-dimensional but not two-dimensional conditions \[[@CR16]\]. This also occurs in mesothelioma \[[@CR21]\] and ovarian carcinoma cells \[[@CR17]-[@CR19]\] expressing low levels of the merlin tumor suppressor protein \[[@CR18],[@CR21]\]. The 50% inhibitory concentration (IC50) for FAK Y397 phosphorylation in MDA-MB-231 breast carcinoma cells is approximately 0.1 μM (Additional file [1](#MOESM1){ref-type="media"}: Figure S1A) and this is similar to results obtained with 4T1L murine breast carcinoma cells using a different (PND-1186, renamed VS-4718) FAK inhibitor \[[@CR16]\].

Here, we tested the effects of FAK inhibitor (0.1 μM, PF-271) addition on the two- and three-dimensional growth of human breast cancer cells. No growth differences were observed after 3 days in adherent two-dimensional culture (Figure [1](#Fig1){ref-type="fig"}A and Additional file [1](#MOESM1){ref-type="media"}: Figure S1B). This is consistent with studies showing that PF-271 (up to 1.0 μM) did not prevent prostate or pancreatic cancer cell growth in culture \[[@CR37],[@CR40],[@CR41]\]. Although BT474 and MDA-MB-468 colony growth in methylcellulose was not affected, 0.1 μM PF-271 addition inhibited MCF7, MDA-MB-231, and 4T1L anchorage-independent three-dimensional colony growth (Figure [1](#Fig1){ref-type="fig"}B and Additional file [1](#MOESM1){ref-type="media"}: Figure S1C). Interestingly, NS knockdown also prevents three-dimensional growth of MCF7 and MDA-MB-231 cells \[[@CR31]\]. Immunoblotting analyses revealed that whereas FAK Y397 phosphorylation was inhibited in all cells by 0.1 μM PF-271 treatment (Figure [1](#Fig1){ref-type="fig"}C), PF-271 reduced NS levels only in MCF7, MDA-MB-231, and 4T1L cells (Figure [1](#Fig1){ref-type="fig"}C and D). No PF-271-associated effects were observed on B23 (nucleophosmin) or nucleolin (Figure [1](#Fig1){ref-type="fig"}C and Additional file [1](#MOESM1){ref-type="media"}: Figure S1D) and low NS levels were not altered by PF-271 treatment of BT474 or MDA-MB-468 cells (Figure [1](#Fig1){ref-type="fig"}C and D). Together, these results support a connection between FAK activity and NS levels in a subset of breast carcinoma tumor cells.Figure 1**Pharmacological focal adhesion kinase (FAK) inhibition selectively reduces nucleostemin (NS) levels and impacts anchorage-independent spheroid breast carcinoma growth. (A, B)** Growth of dimethyl sulfoxide (DMSO)- or PF-271 (0.1 μM)-treated cells: MCF7, BT474, 468 (MDA-MB-468), 231 (MDA-MB-231), and 4T1L in adherent conditions for 3 days **(A)** or methylcellulose for 25 days **(B)**. Values are means expressed as percent of DMSO control. **(C)** Representative lysates of the indicated cells treated with DMSO or PF-271 for 3 days and immunoblotted for pY397 FAK, total FAK, NS (light and dark exposures), B23, and actin. **(D)** Ratio of NS to actin levels in PF-271-treated and control cells determined by densitometry. **(E, F)** Immunoblots from tumor lysates (n = 5 independent controls and 5 treated with VS-4718) quantified by densitometry for MDA-MB-231 and 4T1L cells grown orthotopically in mice and treated with 5% sucrose (control) or 0.5 mg/kg VS-4718 \[[@CR15]\]. Shown is the ratio of pY397 FAK to total FAK, NS to actin, and B23 to actin. The mean of vehicle-treated tumors was set to 1. **(G)** Anti-NS immunoblotting of MDA-MB-231 cells with lentiviral shRNA-mediated NS knockdown (NS-1 and NS-2) compared to scrambled (Scr) control. **(H, I)** Growth of MDA-MB-231 Scr, shRNA NS-1 or NS-2 cells in methylcellulose over 25 days **(H)** or adherent culture over 5 days **(I)**. For all graphs, values are means (+/− SEM, \**P* \<0.05, \*\**P* \<0.01, \*\*\**P* \<0.001, \*\*\*\**P* \<0.0001) of triplicate points from experiments repeated three times.

Previous studies showed that orthotopic MDA-MB-231 and 4T1L tumor growth were inhibited by oral administration of the FAK inhibitor VS-4718 \[[@CR15]\]. Additional analyses of tumor lysates from these experiments revealed decreased FAK Y397 phosphorylation, reduced NS levels, but no changes in B23 expression (Figure [1](#Fig1){ref-type="fig"}E and F). To confirm the importance of NS expression for MDA-MB-231 growth, two different shRNAs were stably-expressed by puromycin selection, and resulted in NS knockdown \>75% in MDA-MB-231 cells (Figure [1](#Fig1){ref-type="fig"}G). NS knockdown but not expression of Scr shRNA control, prevented MDA-MB-231 colony growth in methylcellulose but not in two-dimensional adherent culture (Figure [1](#Fig1){ref-type="fig"}H and I). Interestingly, Kaplan-Meier analyses of a large tumor microarray database revealed that higher FAK, NS, and B23 mRNA levels were associated with decreased patient survival over 10 years (Additional file [2](#MOESM2){ref-type="media"}: Figure S2). As FAK inhibition can impact NS levels in tumors, our results support the notion that FAK and NS may be part of a signaling axis promoting breast carcinoma tumor progression.

Genetic FAK inhibition decreases MDA-MB-231 growth in methylcellulose and reduces NS protein but not mRNA levels {#Sec18}
----------------------------------------------------------------------------------------------------------------

To support the linkage between FAK inhibition and decreased NS levels, lentiviral transduction was used to overexpress GFP or GFP fusions of FAK-WT or FAK-KD (K454R, kinase-dead) in MCF7 cells (Figure [2](#Fig2){ref-type="fig"}A). Immunoblotting revealed a selective reduction in NS but not B23 nucleolar protein levels by GFP-FAK-KD expression (Figure [2](#Fig2){ref-type="fig"}A). In a related approach, lentiviral anti-FAK shRNA was used to knock down endogenous FAK expression in MDA-MB-231 cells. Interestingly, stable FAK knockdown (approximately 50%) was not sufficient to alter steady-state NS levels (Figure [2](#Fig2){ref-type="fig"}B). However, upon stable re-expression of GFP-FAK-WT (herein termed FAK-WT) or GFP-FAK-KD (herein termed FAK-KD) in anti-FAK shRNA-expressing MDA-MB-231 cells, NS levels were reduced by approximately 60% in FAK-KD cells but not altered in FAK-WT cells (Figure [2](#Fig2){ref-type="fig"}B and C). These results support the notion that FAK activity facilitates the maintenance of NS expression in MCF7 and MDA-MB-231 cells.Figure 2**Genetic focal adhesion kinase (FAK) inhibition impacts MDA-MB-231 spheroid growth and lowers nucleostemin (NS) protein levels. (A)** MCF7 cells over-expressing green fluorescent protein (GFP), GFP-FAK-wild-type (WT), or GFP-FAK-kinase-dead (KD) were analyzed for pY397 FAK, total FAK, NS, B23, and actin levels by immunoblotting. **(B)** MDA-MB-231 cells were transduced with lentiviral scrambled (Scr) or anti-human FAK shRNA. Murine GFP-FAK-WT (FAK-WT) or GFP-FAK-KD (FAK-KD) were stably re-expressed in FAK shRNA MDA-MB-231 cells. Immunoblotting of total FAK, NS, and actin. **(C)** Densitometry of NS to actin ratios. Values are means ± SD of triplicate points (\**P* \<0.05) from three independent experiments. **(D)** Histogram of GFP fluorescence as determined by flow cytometry. **(E)** Adherent growth of FAK-WT and FAK-KD MDA-MB-231 cells. Values are means (± SEM) of triplicate points from two independent experiments. **(F)** Representative colony growth in methylcellulose (31 days) of FAK-WT and FAK-KD MDA-MB-231 cells. Scale is 0.5 mm. **(G)** Colony number of FAK-WT and FAK-KD MDA-MB-231 cells. Values are means ± SEM of triplicate points (\*\*\**P* \<0.001) from two independent experiments. **(H)** Immunoblotting for pY397 FAK, total FAK, NS, B23, and actin in FAK-WT and FAK-KD MDA-MB-231 cells. **(I)** qPCR analyses of NS mRNA levels from FAK-WT and FAK-KD MDA-MB-231 cells. Fold change as compared to actin (± SEM) is shown. Data represent triplicate points from three independent experiments. N.S., no significant difference. **(J)** NS, B23, and actin immunoblotting analyses from FAK-WT and FAK-KD MDA-MB-231 cells cultured in methylcellulose for 3 days, and treated or not 3 hours prior to cell lysis (as indicated) with MG132 proteasome inhibitor (40 μM).

By flow cytometry, GFP-FAK-KD was expressed at slightly higher levels than GFP-FAK-WT (Figure [2](#Fig2){ref-type="fig"}D). FAK-KD did not affect MDA-MB-231 adherent growth in culture (Figure [2](#Fig2){ref-type="fig"}E). However, FAK-KD significantly decreased anchorage-independent spheroid growth (*P* \<0.001) (Figure [2](#Fig2){ref-type="fig"}F and G). Cell cycle analyses of FAK-WT and FAK-KD spheroids from methylcellulose colonies revealed a higher percentage of FAK-KD cells in G0/G1 and a lower percentage of cells in G2 compared to FAK-WT spheroids (Additional file [3](#MOESM3){ref-type="media"}: Figure S3). These results support the notion that FAK activity is selectively important in promoting anchorage-independent MDA-MB-231 cell proliferation.

Immunoblotting analyses of FAK-KD spheroids revealed decreased FAK pY397 phosphorylation and lower steady state levels of NS but not B23 compared to FAK-WT cells (Figure [2](#Fig2){ref-type="fig"}H). This difference was not associated with alterations in NS mRNA levels as analyzed by quantitative PCR (Figure [2](#Fig2){ref-type="fig"}I). However, addition of MG132 proteasome inhibitor to FAK-KD MDA-MB-231 cells for 3 hours was sufficient to restore NS levels equivalent to FAK-WT cells (Figure [2](#Fig2){ref-type="fig"}J). As it is known that NS is subject to ubiquitination and degradation \[[@CR34]\], our results support the hypothesis that FAK activity is important in protecting NS protein from proteasomal degradation and that this linkage may enable MDA-MB-231 anchorage-independent spheroid growth.

Genetic FAK inhibition impairs orthotopic tumor growth associated with lower tumor-associated NS {#Sec19}
------------------------------------------------------------------------------------------------

To determine whether MDA-MB-231 spheroid growth alterations results in altered tumor growth, FAK-WT or FAK-KD cells were orthotopically implanted into the breast fat pad of NOD/SCID mice (Figure [3](#Fig3){ref-type="fig"}). FAK-KD tumor volume was significantly lower compared to FAK-WT from Day 33 to Day 57 (Figure [3](#Fig3){ref-type="fig"}A). Mice bearing FAK-WT tumors at day 57 were larger (Figure [3](#Fig3){ref-type="fig"}B and C) and exhibited increased spontaneous metastasis from breast to lung (Figure [3](#Fig3){ref-type="fig"}D) compared to FAK-KD-bearing mice. Immunoblotting analyses of primary tumor lysates showed significantly decreased FAK Y397 phosphorylation and lower NS levels in seven independent FAK-KD tumors compared to FAK-WT samples (Figure [3](#Fig3){ref-type="fig"}E and F). Importantly, tumor levels of other nucleolar proteins such as B23 or nucleolin, respectively, were not different (Figure [3](#Fig3){ref-type="fig"}E and F). NS expression in FAK-WT tumors was higher than FAK-KD MDA-MB-231 tumors as confirmed by immunohistochemical staining of paraffin sections (Figure [3](#Fig3){ref-type="fig"}G). Analyses of FAK-IPs from FAK-WT and FAK-KD tumor lysates revealed the enhanced association of B23 with FAK-WT, but not with FAK-KD (Figure [3](#Fig3){ref-type="fig"}H). As B23 is a binding partner of NS in the nucleolus \[[@CR42]\], we speculate that FAK interactions with B23, possibly in a sub-compartment such as the nucleolus, may facilitate NS regulation impacting breast tumor growth.Figure 3**Focal adhesion kinase (FAK)-kinase-dead (KD) MDA-MB-231 tumors are small with low nucleostemin (NS) levels. (A)** Mean volume of FAK-WT (black, n = 8) and FAK-KD (gray, n = 9) MDA-MB-231 cells grown as orthotopic breast tumors in NOD/SCID mice from day 33 to 57 (± SEM, \**P* \<0.05, \*\**P* \<0.01; \*\*\**P* \<0.001). **(B)** Final FAK-WT or FAK-KD tumor mass at day 57. Values are means (± SEM, \*\*\**P* \<0.001). **(C)** Representative images of FAK-WT and FAK-KD tumors at day 57 (scale 0.5 cm.) **(D)** Mean number of spontaneous breast to lung metastases as visualized by fluorescence (+/− SEM, \* *P* \<0.05). **(E)** Protein lysates from FAK-WT (n = 7) or FAK-KD (n = 7) MDA-MB-231 tumors analyzed by immunoblotting for pY397 FAK, total FAK, nucleolin, NS, B23, and actin. **(F)** Immunoblots in panel E were quantified by densitometry. Values (from seven tumors) are means (± SEM) and displayed as the ratio of FAK pY397 to total FAK, nucleolin to actin, NS to actin, and B23 to actin. FAK-WT values for each comparison were set to 1 (\**P* \<0.05, \*\**P* \<0.01). **(G)** Representative anti-NS immunohistochemical staining (diaminobenzidine, DAB) of FAK-WT and FAK-KD tumors. Tumors were counterstained with methyl green (scale 100 μm). **(H)** FAK immunoprecipitates (IPs) from three FAK-WT and three FAK-KD tumors were analyzed for associated B23 nucleolar protein by immunoblotting.

Active FAK localization to the nucleolus in breast cancer cells {#Sec20}
---------------------------------------------------------------

In adherent cells, FAK localizes to sites of integrin adhesion. However, upon pharmacological FAK inhibition, conditions of cellular stress, or analyses of cells under anchorage-independent conditions, FAK nuclear distribution increases \[[@CR22]\]. Nuclear FAK can alter gene expression and provide a kinase-independent survival signal to cells \[[@CR23],[@CR24]\]. To determine the intracellular distribution of FAK in adherent and suspended MDA-MB-231 cells, biochemical fractionation was performed (Figure [4](#Fig4){ref-type="fig"}A). Cytoplasmic, nucleoplasmic (nuclear extract minus nucleolus), and purified nucleoli fractions were analyzed by immunoblotting for GFP-FAK, activated FAK (pY397 FAK phosphorylation), Lamin B (nucleoplasmic marker), GAPDH (cytoplasmic marker), and B23 (nucleolar marker) (Figure [4](#Fig4){ref-type="fig"}B). The majority of FAK-WT and FAK-KD were in the cytoplasmic fraction with lower levels detected in the nucleoplasmic fraction. Both FAK-WT and FAK-KD were present in the nucleoplasm and this did not change upon holding MDA-MB-231 cells in suspension for 4 h (Figure [4](#Fig4){ref-type="fig"}B). Interestingly, FAK-WT phosphorylated at Y397 was associated with purified nucleoli from adherent cells and the amount of nucleolar and Y397 phosphorylated FAK-WT increased upon holding MDA-MB-231 cells in suspension for 4 h (Figure [4](#Fig4){ref-type="fig"}B and C). Surprisingly, nucleoli from suspended cells contained only low levels of FAK-KD that was not phosphorylated (Figure [4](#Fig4){ref-type="fig"}B and C). These results support the hypothesis that FAK activity is important in promoting its nucleolar localization.Figure 4**Active focal adhesion kinase (FAK) associates with nucleoli in breast carcinoma cells. (A)** Cell fractionation protocol for cytoplasmic, nucleoplasmic, and nucleolar isolation. **(B)** FAK pY397, total FAK, Lamin B, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and B23 immunoblotting analyses of FAK-WT and FAK-KD reconstituted MDA-MB-231 fractionation from adherent (0 h) and cells held in suspension for 4 h. FAK-WT and FAK-KD were detected within cytoplasmic and nucleoplasmic fractions. Greater FAK-WT levels and Y397 phosphorylated FAK were associated with purified nucleoli compared to FAK-KD. **(C)** Ratio of GFP-FAK to B23 levels determined by densitometry: means ± SD from three independent experiments with FAK-WT at 0 h set to 1 (\**P* \<0.05, \*\**P* \<0.01). **(D)** Representative confocal microscopy of green fluorescent protein (GFP)-FAK wild-type (WT) fluorescence and nuclei staining. Merge shows Hoechst (blue) and nucleolar GFP-FAK-WT (green) localization (arrows). Medial confocal section (scale 50 μm). **(E)** Representative pY397 FAK staining in paraffin-embedded normal and human breast carcinoma tumors. Normal breast contains little pY397 FAK signal; invasive ductal carcinoma (IDC) exhibits both cytoplasmic (right) and nuclear-associated anti-pY397 FAK staining (brown). Inset, higher magnification shows punctate pY397 FAK staining (arrows) within nuclei. Slides were counterstained with hematoxylin (scale 25 μm).

To determine if nucleolar FAK localization could be visualized in intact cells, adherent GFP-FAK-WT cells were imaged by confocal microscopy. Strong GFP-FAK-WT fluorescence was detected in a sub-compartment of the nucleus (Figure [4](#Fig4){ref-type="fig"}D, arrows and Additional file [4](#MOESM4){ref-type="media"}: Figure S4A). GFP-FAK-KD or expression of GFP alone in MDA-MB-231 cells did not exhibit this pattern of nucleolar localization as did GFP-FAK-WT (Additional file [4](#MOESM4){ref-type="media"}: Figure S4A and B). To determine if nucleoli-localized active FAK could be detected in breast tumors, a tissue micro-array containing normal breast and invasive ductal carcinoma (IDC) samples were stained with a monoclonal antibody to FAK pY397 (Figure [4](#Fig4){ref-type="fig"}E). Previous studies have shown that FAK expression is low in normal breast tissue and increases as a function of tumor grade and stage \[[@CR7]\]. We find that normal breast tissue is weakly stained for pY397 FAK and the majority of IDC samples exhibit strong cytoplasmic or membrane-associated pY397 FAK staining (Figure [4](#Fig4){ref-type="fig"}E). However, in a subset of IDC tissues, strong nuclear- and nucleoli-localized pY397 FAK staining was detected (Figure [4](#Fig4){ref-type="fig"}E, arrows). These results support a signaling role for nucleolar-associated FAK in breast carcinoma cells that is distinct from a canonical integrin adhesion-dependent mechanism.

Akt activation can prevent NS loss by FAK inhibition {#Sec21}
----------------------------------------------------

To determine if a complex between FAK and NS could be detected, MDA-MB-231 cells were transfected with GFP or GFP-NS (N-terminal fusion). GFP-NS exhibited sub-compartment localization within nuclei, whereas GFP was distributed throughout cells (Figure [5](#Fig5){ref-type="fig"}A). Co-immunoprecipitation assays with antibodies to GFP revealed a complex of mTOR, FAK, and Akt with GFP-NS and not GFP alone (Figure [5](#Fig5){ref-type="fig"}B). To determine if FAK inhibition alters Akt or mTOR activation in breast carcinoma cells, lysates of MCF7, BT474, MDA-MB-468, MDA-MB-231, and 4T1L treated with DMSO (control) or 0.1 μM PF-271 FAK inhibitor for 3 days were evaluated by immunoblotting (Figure [5](#Fig5){ref-type="fig"}C). BT474 and MDA-MB-468 cells maintained elevated phosphorylated serine-473 (pS473) Akt in the presence of PF-271 (Figure [5](#Fig5){ref-type="fig"}C). This is consistent with *PIK3CA* and *PTEN* mutations in BT474 and MDA-MB-468 cells, respectively (Table [1](#Tab1){ref-type="table"}). However, reduced pS473 Akt phosphorylation occurred in MCF7, MDA-MB-231, and 4T1L cells with PF-271 addition (Figure [5](#Fig5){ref-type="fig"}C). In MDA-MB-231 and 4T1L cells, 0.1 μM PF-271 also decreased serine-65 (pS65) phosphorylation of 4E-binding protein 1 (4E-BP1) \[[@CR43]\], a translation repressor protein and target the mTOR complex (Figure [5](#Fig5){ref-type="fig"}C, \#). In MDA-MB-468 cells, PF-271 did not reduce either Akt or 4E-BP1 phosphorylation (Figure [5](#Fig5){ref-type="fig"}C) and these cells were insensitive to PF-271-mediated regulation of NS (Figure [1](#Fig1){ref-type="fig"}C). In MDA-MB-231 tumor lysates, genetic FAK inhibition (FAK-KD) was associated with decreased pS65 4E-BP1 phosphorylation (Figure [5](#Fig5){ref-type="fig"}D). These results support the notion that FAK may stimulate Akt-mTOR pathway activation that may act to stabilize NS protein levels.Figure 5**Activated Akt can prevent nucleostemin (NS) loss by focal adhesion kinase (FAK) inhibition; connections to mammalian target of rapamycin (mTOR) as analyzed by pS65 4E-BP1 phosphorylation and rapamycin inhibition. (A)** Representative fluorescence confocal microscopy of MDA-MB-231 cells transfected with green fluorescent protein (GFP) or GFP-NS (24 h) (scale 50 μm). **(B)** Anti-GFP antibody co-immunoprecipitation (IP) of MDA-MB-231 cells transfected with GFP or GFP-NS. Shown is immunoblotting (IB) for GFP, mTOR, FAK, and Akt. **(C)** Lysates of dimethyl sulfoxide (DMSO)- or PF-271-treated (0.1 μM, 72 h) from adherent cells and immunoblotted for pS473 Akt, total Akt, pS65 4E-BP1, and actin. Reduction in pS473 Akt and pS65 4E-BP1 in PF-271-treated MDA-MB-231 and 4T1L cells (lanes indicated by \#). **(D)** FAK-wild-type (WT) and FAK-kinase-dead (KD) MDA-MB-231 tumor lysates were immunoblotted for pS65 4E-BP1 and quantified by densitometry. Values are means (± SEM) and displayed as the ratio of pS65 4E-BP1 to actin. FAK-WT values were set to 1 (\**P* \<0.05). **(E)** Stable expression of myristoylated - activated Akt (Akt\*) in FAK-WT and FAK-KD MDA-MB-231 cells. Lysates were immunoblotted for pS473 Akt, total Akt, NS, B23, pS65 4E-BP1 and actin. **(F)** Colony formation of control (CTRL) and Akt\*-expressing in FAK-WT and FAK-KD MDA-MB-231 cells. Values are means (± SEM, \*\**P* \<0.01) of triplicate points. **(G)** MDA-MB-468 cells treated with PF-271 or rapamycin for 1 h (adherent) and lysates evaluated by pY397 FAK, total FAK, NS, B23, pS473 Akt, total Akt, pS65 4E-BP1, and actin immunoblotting. Blots are from one representative experiment repeated three times.

To test the importance of Akt activity in this linkage, constitutively-active Akt (myristylated-Akt, Akt\*) was stably expressed in FAK-WT and FAK-KD MDA-MB-231 cells. Enhanced Akt activity was confirmed by elevated pS473 Akt phosphorylation in both FAK-WT and FAK-KD cells (Figure [5](#Fig5){ref-type="fig"}E). Importantly, Akt\* expression resulted in elevated steady-state NS levels and increased 4E-BP1 phosphorylation in FAK-KD cells. Akt\* expression was sufficient to rescue FAK-KD MDA-MB-231 colony growth in methylcellulose equal to control FAK-WT levels (Figure [5](#Fig5){ref-type="fig"}F). These results demonstrate that activated Akt expression can promote colony growth and prevent NS loss associated with FAK inhibition.

Rapamycin lowers NS levels in MDA-MB-468 cells with activated Akt {#Sec22}
-----------------------------------------------------------------

PF-271-mediated FAK inhibition did not alter NS levels in MDA-MB-468 cells that exhibit high levels of Akt and 4E-BP1 phosphorylation. DNA sequencing of MDA-MB-468 cells has revealed mutations in the phosphatase and tensin homolog (PTEN) protein that acts as a negative regulator of the Akt signaling pathway (Table [1](#Tab1){ref-type="table"}). To evaluate the importance of mTOR activation in maintaining NS protein levels, MDA-MB-468 cells were treated with rapamycin (0.1 μM for 1 h), an inhibitor of mTOR complex (Figure [5](#Fig5){ref-type="fig"}G). Rapamycin treatment decreased NS levels and reduced 4E-BP1 phosphorylation. This was independent of effects on FAK or Akt phosphorylation. These results support the importance of mTOR activity in maintaining NS levels in MDA-MB-468 cells.

Discussion {#Sec23}
==========

FAK inhibitors are being evaluated in several clinical trials with an underlying rationale that effects are mediated through alterations in both tumor and stromal cell function \[[@CR6]\]. FAK inhibitory effects on tumor cells involve the prevention of cell motility and invasion *in vitro* as well as tumor growth and metastasis in mouse models. FAK inhibitor administration can slow tumor growth and trigger increased tumor cell apoptosis *in vivo* \[[@CR15],[@CR37]\]. Although this may be due in part to angiogenesis prevention \[[@CR44]\], studies are beginning to uncover selective roles for FAK signaling when tumor cells are grown as spheroids *in vitro* \[[@CR16]-[@CR19]\]. Importantly, nanomolar sensitivity to FAK inhibition is not observed using standard monolayer cell culture. However, some tumor cells exhibit insensitivity as three-dimensional spheroids to micromolar FAK inhibitor levels \[[@CR18]\]. Elucidating the molecular basis for these differential effects will provide fundamental knowledge of how best to apply FAK inhibitor treatment in clinical settings.

Herein, we identify a new linkage between FAK activity and the nucleolar protein, nucleostemin (NS), in the regulation of anchorage-independent spheroid and orthotopic breast carcinoma growth as tumors. Genetic or pharmacological FAK inhibition was associated with decreased NS levels but not other nucleolar proteins such as B23 (nucleophosmin) or nucleolin in cell culture and in tumors. NS knockdown prevented MDA-MB-231 cell growth as spheroids but was not essential for growth in two-dimensional culture. FAK inhibition did not alter NS mRNA levels and proteasomal inhibition stabilized NS upon FAK inhibition. These results support the importance of FAK activity in protecting NS protein from proteasomal degradation and we hypothesize that this may enable MDA-MB-231 anchorage-independent growth. However, NS over-expression in MDA-MB-231 cells did not promote anchorage-independent growth in the presence of FAK inhibition (I. Tancioni, unpublished) and cells expressing high basal NS levels (MDA-MB-231 and 4T1L) are not resistant to FAK inhibitor growth inhibition. Thus, high NS levels are not predictive of FAK inhibitor resistance.

Nevertheless, it is intriguing that both FAK and NS can control common stem cell-like properties of tumor cells such as anchorage-independent growth \[[@CR21],[@CR31]\]. Since tumor cells are not making canonical focal adhesions as three-dimensional spheroids, we investigated the distribution of active FAK by cellular fractionation. An increased percentage of active GFP-FAK-WT was associated with purified nucleoli following cell suspension for 4 hours. Surprisingly, although GFP-FAK-KD was present in the nucleoplasmic fraction, only low levels of GFP-FAK-KD were found in purified nucleoli. The mechanism(s) directing active FAK to the nucleolus remain under investigation. For FAK-WT, nucleolar localization was detected by confocal microscopy and a subset of invasive ductal breast carcinoma tumors exhibited nucleolar staining with antibodies to pY397 FAK. These results are consistent with phosphoproteomic studies showing that Y397 FAK was elevated in stem cell spheroid clusters \[[@CR45]\] and that nuclear active FAK is associated with a poor prognosis in human colorectal cancer \[[@CR46]\]. As FAK-WT co-immunoprecipitates with B23, and NS forms a complex with B23 in the nucleolus \[[@CR42]\], our studies support a signaling role for active nucleolar-associated FAK that is distinct from a canonical integrin adhesion linkage mechanism.

Expression of a GFP-tagged NS construct localized to nucleolar sites in MDA-MB-231 cells and formed a complex with FAK, Akt, and mTOR as determined by co-immunoprecipitation. Interestingly, mTOR Complex 1 can localize to the nucleolus and nuclear Akt interacts with B23, leading to protection from proteolytic cleavage and enhancement of cell survival \[[@CR47],[@CR48]\]. This led us to explore whether connections may exist between FAK, Akt, and mTOR in the regulation of NS levels. Indeed, expression of constitutively-active Akt promoted colony growth and stabilized NS levels in the presence of inhibited FAK. Further, rapamycin inhibition of mTOR lowered NS levels in *PTEN*-mutated MDA-MB-468 breast carcinoma cells. These results support a FAK to Akt to mTOR signaling linkage in the regulation of NS levels. As elevated FAK expression in breast cancer is associated with a triple-negative cell phenotype \[[@CR49]\], our results support a model whereby FAK activity-mediated modulation of NS levels may be part of a mesenchymal- or stem cell-associated regulatory circuit. Combinational use of FAK and PI3K-mTOR inhibitors \[[@CR50]\] may have additive effects in breast cancers that show resistance to standard therapies.

Conclusions {#Sec24}
===========

This study shows that FAK activity regulates nucleostemin (NS) levels, a nucleolar protein involved in promoting breast tumor growth. FAK activity and NS are selectively required for anchorage-independent MDA-MB-231 spheroid growth and cell fractionation analyses revealed active FAK association with nucleoli upon holding MDA-MB-231 cells in suspension. Activation of Akt stabilized NS levels and promoted anchorage-independent growth in the presence of inactivated FAK. As rapamycin lowered NS levels in *PTEN*-mutated MDA-MB-468 breast carcinoma cells, our studies support a role for nucleolar-associated FAK signaling and Akt-mTOR activation in the maintenance of NS protein expression. Reduction in NS levels may serve as a protein biomarker of FAK inhibitor effectiveness in breast cancer therapy.

Additional files {#Sec25}
================

Additional file 1: Figure S1.Pharmacological focal adhesion kinase (FAK) inhibition prevents breast carcinoma growth in methylcellulose but not in adherent conditions. (**A**) Dose-dependent inhibition of FAK pY397 phosphorylation by PF-271. MDA-MB-231 cells were treated with vehicle (dimethyl sulfoxide (DMSO)) or increasing concentrations of PF-271 for 1 hour and lysates immunoblotted for pY397 FAK, total FAK, and actin. The ratio between pY397FAK and FAK of DMSO was set to 1. (**B**) The indicated breast carcinoma cells were grown in presence of DMSO or PF-271 (0.1 μM) for 3 days and imaged by phase contrast microscopy. Scale is 100 μm. (**C**) The indicated breast carcinoma cells were grown in presence of DMSO or PF-271 (0.1 μM) for 25 days in methylcellulose and imaged by phase contrast microscopy. Scale is 500 μm. (**D**) Lysates of DMSO- or 0.1 μM PF-271-treated (3 days) MCF7, BT474, 468 (MDA-MB-468), 231 (MDA-MB-231) cells and immunoblotted for pY397 FAK, total FAK, nucleolin, and actin. Additional file 2: Figure S2.Association of focal adhesion kinase (FAK), nucleostemin, and B23 mRNA levels with breast cancer patient overall survival. Kaplan-Meier analyses of FAK, nucleostemin, B23, and nucleolin mRNA levels in 741 patient samples. High (red) versus low (black) mRNA expression shows overall patient survival over 120 months. Log-rank *P*-values for significance are shown (inset). Additional file 3: Figure S3.Focal adhesion kinase- (FAK)-kinase-dead (KD) MDA-MB-231 cells show higher percentage of cells in G0/G1 phase than wild-type (WT)-FAK cells. FAK-WT and FAK-KD MDA-MB-231 cells cultured in methylcellulose for 3 days were collected, stained with propidium iodide, and analyzed by flow cytometry. Representative histogram of cell cycle analyses and percentage of cells in Sub-G1, G0/G1, S, and G2 phases of the cell cycle as analyzed by FlowJo software. Additional file 4: Figure S4.Green fluorescent protein-focal adhesion kinase-wildtype (GFP-FAK-WT) nucleolar localization. (**A**) Representative confocal microscopy images of re-expressing GFP-FAK-WT and GFP-FAK-kinase-dead (KD) MDA-MB-231 cells (Hoechst nuclear stain, blue) reveal nucleolar GFP-FAK-WT localization (arrows). GFP-FAK-KD is primarily cytoplasmic in the confocal image. (**B**) Representative confocal images of MDA-MB-231 expressing GFP-FAK-WT or GFP. Scale is 50 μm.
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